Author | Michael Swanick

Articles

Brexit Report: What's Next for the Industry?

Pharmaceutical Executive

Article

As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.

Beyond 2020: Building Strategic Coherence in the New Health Economy

Pharmaceutical Executive

Article

Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?

Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015

Pharmaceutical Executive

Article

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.    

Dealmaking: Staying Ahead of the Curve

Pharmaceutical Executive

Article

Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?